

# Roger A. Barker

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1841763/roger-a-barker-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

385  
papers

26,102  
citations

85  
h-index

149  
g-index

420  
ext. papers

30,610  
ext. citations

7.6  
avg, IF

7.13  
L-index

#	Paper	IF	Citations
385	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. <i>Movement Disorders Clinical Practice</i> , <b>2022</b> , 9, 479-483	2.2	0
384	Metacognitive insight into cognitive performance in Huntington's disease gene carriers.. <i>BMJ Neurology Open</i> , <b>2022</b> , 4, e000268	1.5	
383	Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.. <i>PLoS Computational Biology</i> , <b>2022</b> , 18, e1010079	5	1
382	The sleep and circadian problems of Huntington's disease: when, why and their importance. <i>Journal of Neurology</i> , <b>2021</b> , 268, 2275-2283	5.5	4
381	Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease. <i>Brain</i> , <b>2021</b> , 144, 2513-2526	11.2	6
380	Early constipation predicts faster dementia onset in Parkinson's disease. <i>Npj Parkinson's Disease</i> , <b>2021</b> , 7, 45	9.7	6
379	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. <i>Nature Genetics</i> , <b>2021</b> , 53, 787-793	36.3	15
378	The coding and long noncoding single-cell atlas of the developing human fetal striatum. <i>Science</i> , <b>2021</b> , 372,	33.3	11
377	MEIS-WNT5A axis regulates development of fourth ventricle choroid plexus. <i>Development (Cambridge)</i> , <b>2021</b> , 148,	6.6	3
376	Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 1772-1780	7	8
375	Single cell derived mRNA signals across human kidney tumors. <i>Nature Communications</i> , <b>2021</b> , 12, 3896	17.4	4
374	Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 87, 61-69	3.6	1
373	Late-onset Huntington's disease associated with CAG repeat lengths of 30 and 31. <i>Journal of Neurology</i> , <b>2021</b> , 268, 3916-3919	5.5	1
372	ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. <i>Stem Cell Reports</i> , <b>2021</b> , 16, 1398-1408	8	27
371	Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 263-264	7	1
370	Differences in the Presentation and Progression of Parkinson's Disease by Sex. <i>Movement Disorders</i> , <b>2021</b> , 36, 106-117	7	16
369	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 171-177	7	1

368	The Treatment of Sleep Dysfunction in Neurodegenerative Disorders. <i>Neurotherapeutics</i> , <b>2021</b> , 18, 202-216	8	
367	Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 424-433	7	27
366	Systemic $\beta$ synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson's disease. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 556-567	15.1	10
365	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	23
364	Transvascular delivery of $\beta$ synuclein preformed fibrils, using the RVG9R delivery system, generates $\beta$ synuclein pathology in the duodenal myenteric plexus of non-transgenic rats. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 365-365	15.1	1
363	The Origins of the Protein Spread in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 1194-1197	2.2	
362	Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 1297-1308	5.3	1
361	Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson's Disease to the Clinic: The Investigator's Perspective. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, S129-S134	5.3	1
360	Cells of the human intestinal tract mapped across space and time. <i>Nature</i> , <b>2021</b> , 597, 250-255	50.4	40
359	A roadmap for the Human Developmental Cell Atlas. <i>Nature</i> , <b>2021</b> , 597, 196-205	50.4	18
358	Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease. <i>Stem Cells</i> , <b>2020</b> , 38, 936-947	5.8	9
357	Parkinson's disease and spirituality. <i>NeuroRehabilitation</i> , <b>2020</b> , 46, 31-39	2	0
356	3D-Printed Soft Lithography for Complex Compartmentalized Microfluidic Neural Devices. <i>Advanced Science</i> , <b>2020</b> , 7, 2001150	13.6	18
355	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 76, 49-53	3.6	3
354	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 1047-1055	5.3	3
353	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 875-891	5.3	28
352	Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease. <i>Movement Disorders</i> , <b>2020</b> , 35, 1062-1066	7	16
351	Informed Consent for Stem Cell-Based Interventions-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 894	27.4	

350	Altered subcortical emotional salience processing differentiates Parkinson's patients with and without psychotic symptoms. <i>NeuroImage: Clinical</i> , <b>2020</b> , 27, 102277	5.3	3
349	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , <b>2020</b> , 87, 473-488	16.6	29
348	A cell atlas of human thymic development defines T cell repertoire formation. <i>Science</i> , <b>2020</b> , 367,	33.3	171
347	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 512-519	5.5	38
346	The Dementias Platform UK (DPUK) Data Portal. <i>European Journal of Epidemiology</i> , <b>2020</b> , 35, 601-611	12.1	23
345	Recent developments in the treatment of Parkinson's Disease. <i>F1000Research</i> , <b>2020</b> , 9,	3.6	32
344	DJ-1 can form sheet structured aggregates that co-localize with pathological amyloid deposits. <i>Neurobiology of Disease</i> , <b>2020</b> , 134, 104629	7.5	10
343	Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease. <i>Chemical Science</i> , <b>2020</b> , 11, 525-533	9.4	10
342	Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort. <i>Movement Disorders</i> , <b>2020</b> , 35, 185-190	7	19
341	Association Between Toll-Like Receptor 4 (TLR4) and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Genetic Variants and Clinical Progression of Huntington's Disease. <i>Movement Disorders</i> , <b>2020</b> , 35, 401-408	7	7
340	Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 193-206	5.3	22
339	Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson's disease. <i>NeuroImage: Clinical</i> , <b>2020</b> , 28, 102409	5.3	3
338	The Clinical Features and Progression of Late-Onset Versus Younger-Onset in an Adult Cohort of Huntington's Disease Patients. <i>Journal of Huntington's Disease</i> , <b>2020</b> , 9, 275-282	1.9	4
337	A blueprint for translational regenerative medicine. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	7
336	Huntingtin-lowering strategies for Huntington's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 1125-1132	5.9	11
335	Animal Models of Parkinson's Disease: Are They Useful or Not?. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 1335-1342	5.3	15
334	Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 1539-1562	6.4	7
333	Microfluidic Neural Devices: 3D-Printed Soft Lithography for Complex Compartmentalized Microfluidic Neural Devices (Adv. Sci. 16/2020). <i>Advanced Science</i> , <b>2020</b> , 7, 2070088	13.6	78

332	A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 858	4.1	13
331	Pro-Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLE-PD. <i>Movement Disorders</i> , <b>2019</b> , 34, 1690-1698	7	12
330	Huntington's disease patients display progressive deficits in hippocampal-dependent cognition during a task of spatial memory. <i>Cortex</i> , <b>2019</b> , 119, 417-427	3.8	12
329	Meaningful and Measurable Health Domains in Huntington's Disease: Large-Scale Validation of the Huntington's Disease Health-Related Quality of Life Questionnaire Across Severity Stages. <i>Value in Health</i> , <b>2019</b> , 22, 712-720	3.3	4
328	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 65, 55-61	3.6	10
327	Targeting Huntingtin Expression in Patients with Huntington's Disease. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 2307-2316	59.2	319
326	Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system. <i>Brain</i> , <b>2019</b> , 142, 2023-2036	11.2	25
325	Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntington's Disease. <i>Journal of Huntington's Disease</i> , <b>2019</b> , 8, 181-193	1.9	2
324	WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis. <i>Nature Communications</i> , <b>2019</b> , 10, 1498	17.4	42
323	The clinical heterogeneity of Parkinson's disease and its therapeutic implications. <i>European Journal of Neuroscience</i> , <b>2019</b> , 49, 328-338	3.5	60
322	A Professional Standard for Informed Consent for Stem Cell Therapies. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1651-1652	27.4	10
321	Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. <i>Brain</i> , <b>2019</b> , 142, 2828-2844	11.2	35
320	Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. <i>Nature Medicine</i> , <b>2019</b> , 25, 1045-1053	50.5	88
319	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , <b>2019</b> , 34, 1839-1850	7	69
318	Dual modulation of neuron-specific microRNAs and the REST complex promotes functional maturation of human adult induced neurons. <i>FEBS Letters</i> , <b>2019</b> , 593, 3370-3380	3.8	10
317	Portrait of blood-derived extracellular vesicles in patients with Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2019</b> , 124, 163-175	7.5	18
316	Disease-Modification in Huntington's Disease: Moving Away from a Single-Target Approach. <i>Journal of Huntington's Disease</i> , <b>2019</b> , 8, 9-22	1.9	2
315	Dynamic and Cell-Specific DACH1 Expression in Human Neocortical and Striatal Development. <i>Cerebral Cortex</i> , <b>2019</b> , 29, 2115-2124	5.1	5

314	Exploring causality of the association between smoking and Parkinson's disease. <i>International Journal of Epidemiology</i> , <b>2019</b> , 48, 912-925	7.8	38
313	Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts. <i>Journal of Visualized Experiments</i> , <b>2018</b> ,	1.6	6
312	Predicting clinical diagnosis in Huntington's disease: An imaging polymarker. <i>Annals of Neurology</i> , <b>2018</b> , 83, 532-543	9.4	15
311	Features of -associated Parkinson's disease at presentation in the UK study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, 702-709	5.5	55
310	Using Medical Claims Analyses to Understand Interventions for Parkinson Patients. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, 45-58	5.3	14
309	Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study. <i>Journal of Neurology</i> , <b>2018</b> , 265, 1528-1539	5.5	24
308	C-PE2I and F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. <i>Movement Disorders</i> , <b>2018</b> , 33, 117-127	7	30
307	Regenerative Therapies for Parkinson's Disease: An Update. <i>BioDrugs</i> , <b>2018</b> , 32, 357-366	7.9	11
306	The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?. <i>Stem Cell Reports</i> , <b>2018</b> , 10, 1429-1431	8	17
305	Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. <i>Cell Reports</i> , <b>2018</b> , 24, 1397-1406	10.6	37
304	Categorising Visual Hallucinations in Early Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, 447-453	5.3	8
303	The motor and cognitive features of Parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series. <i>Journal of Neurology</i> , <b>2018</b> , 265, 1789-1794	5.5	10
302	iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia. <i>Experimental Neurobiology</i> , <b>2018</b> , 27, 350-364	4	15
301	The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 946	4.1	28
300	Outcome of cell suspension allografts in a patient with Huntington's disease. <i>Annals of Neurology</i> , <b>2018</b> , 84, 950-956	9.4	9
299	Multimorbidity Predicts Quality of Life but not Motor Severity in Early Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, 511-515	5.3	4
298	Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 870	4.1	22
297	Platelet-derived extracellular vesicles in Huntington's disease. <i>Journal of Neurology</i> , <b>2018</b> , 265, 2704-2715	5.5	10

296	Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease. <i>Human Gene Therapy Clinical Development</i> , <b>2018</b> , 29, 148-155	3.2	67
295	New approaches for brain repair-from rescue to reprogramming. <i>Nature</i> , <b>2018</b> , 557, 329-334	50.4	100
294	Intra- and inter-network functional alterations in Parkinson's disease with mild cognitive impairment. <i>Human Brain Mapping</i> , <b>2017</b> , 38, 1702-1715	5.9	29
293	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 40, 40-46	3.6	9
292	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , <b>2017</b> , 16, 620-629	24.1	98
291	Normal aging and Parkinson's disease are associated with the functional decline of distinct frontal-striatal circuits. <i>Cortex</i> , <b>2017</b> , 93, 178-192	3.8	17
290	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 55, 78-90	5.6	30
289	Formation of hippocampal mHTT aggregates leads to impaired spatial memory, hippocampal activation and adult neurogenesis. <i>Neurobiology of Disease</i> , <b>2017</b> , 102, 105-112	7.5	6
288	Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 36, 63-68	3.6	31
287	Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 357-365	6	44
286	An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease. <i>Journal of Neurology</i> , <b>2017</b> , 264, 2457-2463	5.5	15
285	Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era. <i>Cell Stem Cell</i> , <b>2017</b> , 21, 569-573	18	193
284	CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0171748	3.7	2
283	Spatial structure normalises working memory performance in Parkinson's disease. <i>Cortex</i> , <b>2017</b> , 96, 73-83	3.8	5
282	Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD). <i>Progress in Brain Research</i> , <b>2017</b> , 230, 165-190	2.9	55
281	REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways. <i>EMBO Molecular Medicine</i> , <b>2017</b> , 9, 1117-1131	12	57
280	Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 5280	4.9	38
279	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 509-516	2.2	18

278	PO088 Nigral iron susceptibility in parkinson's disease: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, A34.4-A35	5.5	
277	Cortical and Striatal Reward Processing in Parkinson's Disease Psychosis. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 156	4.1	3
276	Direct Neuronal Reprogramming for Disease Modeling Studies Using Patient-Derived Neurons: What Have We Learned?. <i>Frontiers in Neuroscience</i> , <b>2017</b> , 11, 530	5.1	35
275	Neural grafting for Parkinson's disease: challenges and prospects. <i>Neural Regeneration Research</i> , <b>2017</b> , 12, 389-392	4.5	24
274	Cell therapies for Parkinson's disease: how far have we come?. <i>Regenerative Medicine</i> , <b>2016</b> , 11, 777-786	2.5	14
273	α-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function. <i>Experimental Neurology</i> , <b>2016</b> , 285, 72-81	5.7	28
272	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. <i>Annals of Neurology</i> , <b>2016</b> , 80, 674-685	9.4	154
271	Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1518-1526	7	90
270	A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson's disease. <i>EMBO Journal</i> , <b>2016</b> , 35, 1963-78	13	52
269	Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?. <i>Journal of Parkinson's Disease</i> , <b>2016</b> , 6, 57-63	5.3	47
268	A simple assessment model to quantifying the dynamic hippocampal neurogenic process in the adult mammalian brain. <i>Hippocampus</i> , <b>2016</b> , 26, 517-29	3.5	6
267	Atomoxetine restores the response inhibition network in Parkinson's disease. <i>Brain</i> , <b>2016</b> , 139, 2235-48	11.2	57
266	Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease. <i>Brain</i> , <b>2016</b> , 139, 161-73	11.2	51
265	Learning to be inflexible: Enhanced attentional biases in Parkinson's disease. <i>Cortex</i> , <b>2016</b> , 82, 24-34	3.8	14
264	The neurology community mourns the passing of Dr. John F. Kurtzke. <i>Journal of Neurology</i> , <b>2016</b> , 263, 421	5.5	
263	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. <i>Movement Disorders</i> , <b>2016</b> , 31, 1020-6	7	38
262	Olfaction in Parkinson single and compound heterozygotes in a cohort of young onset Parkinson's disease patients. <i>Acta Neurologica Scandinavica</i> , <b>2016</b> , 134, 271-6	3.8	20
261	Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 41-52	4	22



260	Characterization and Visualization of Vesicles in the Endo-Lysosomal Pathway with Surface-Enhanced Raman Spectroscopy and Chemometrics. <i>ACS Nano</i> , <b>2016</b> , 10, 307-16	16.7	67
259	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. <i>Lancet Neurology</i> , <b>2016</b> , 15, 585-96	24.1	59
258	Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 1026-37	5.9	42
257	Development and external validation of a prognostic model in newly diagnosed Parkinson disease. <i>Neurology</i> , <b>2016</b> , 86, 986-93	6.5	31
256	Hippocampal dysfunction defines disease onset in Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 975-81	5.5	32
255	Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection. <i>Journal of Parkinson's Disease</i> , <b>2016</b> , 6, 289-300	5.3	18
254	Novel targets for Huntington's disease: future prospects. <i>Degenerative Neurological and Neuromuscular Disease</i> , <b>2016</b> , 6, 25-36	5.4	6
253	F11 Verbal memory in huntington's disease: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, A52.2-A52	5.5	1
252	Exogenous melatonin for Parkinson's disease: 'Waking up' to the need for further trials. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 29, 121-2	3.6	4
251	Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 27, 47-53	3.6	95
250	GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions. <i>Cell Death and Disease</i> , <b>2016</b> , 7, e2206	9.8	40
249	Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. <i>Stem Cell Reports</i> , <b>2016</b> , 6, 787-797	8	136
248	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 33, 96-101	3.6	36
247	Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. <i>Neurobiology of Aging</i> , <b>2016</b> , 48, 153-160	5.6	60
246	Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells. <i>Cell</i> , <b>2016</b> , 167, 566-580	5.6	425
245	Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?. <i>Movement Disorders</i> , <b>2016</b> , 31, 103-10	7	99
244	Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). <i>Movement Disorders</i> , <b>2016</b> , 31, 995-1003	7	119
243	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1062-6	7	36

242	Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1163-72	7	11
241	Review: The spectrum of clinical features seen with alpha synuclein pathology. <i>Neuropathology and Applied Neurobiology</i> , <b>2016</b> , 42, 6-19	5.2	56
240	Cell-based therapies for Parkinson disease—past insights and future potential. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 492-503	15	197
239	Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , <b>2015</b> , 138, 2974-86	11.2	146
238	Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 1519-28	5.6	30
237	Progress in Huntington's disease: the search for markers of disease onset and progression. <i>Journal of Neurology</i> , <b>2015</b> , 262, 1990-5	5.5	6
236	Parkinson's disease: diagnosis and current management. <i>The Prescriber</i> , <b>2015</b> , 26, 16-23	0.4	5
235	The role of the amygdala during emotional processing in Huntington's disease: from pre-manifest to late stage disease. <i>Neuropsychologia</i> , <b>2015</b> , 70, 80-9	3.2	30
234	Dopamine and Huntington's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2015</b> , 15, 445-58	4.3	43
233	Movement disorders and psychiatry: Five new things. <i>Neurology: Clinical Practice</i> , <b>2015</b> , 5, 143-149	1.7	3
232	A novel combinational approach of microstimulation and bioluminescence imaging to study the mechanisms of action of cerebral electrical stimulation in mice. <i>Journal of Physiology</i> , <b>2015</b> , 593, 2257-78	3.9	7
231	The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study. <i>Brain and Behavior</i> , <b>2015</b> , 5, e00312	3.4	46
230	Improving response inhibition in Parkinson's disease with atomoxetine. <i>Biological Psychiatry</i> , <b>2015</b> , 77, 740-8	7.9	69
229	Sleep deficits but no metabolic deficits in premanifest Huntington's disease. <i>Annals of Neurology</i> , <b>2015</b> , 78, 630-48	9.4	70
228	Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease. <i>Journal of Huntingtons Disease</i> , <b>2015</b> , 4, 131-40	1.9	10
227	Rating Apathy in Huntington's Disease: Patients and Companions Agree. <i>Journal of Huntingtons Disease</i> , <b>2015</b> , 4, 49-59	1.9	15
226	Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology. <i>Annals of Neurology</i> , <b>2015</b> , 78, 160-77	9.4	146
225	Tracking Parkinson's: Study Design and Baseline Patient Data. <i>Journal of Parkinsons Disease</i> , <b>2015</b> , 5, 947-59	5.3	31

224	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 743-7	5.3	12
223	Retrospective assessment of movement disorder society criteria for mild cognitive impairment in Parkinson's disease. <i>Journal of the International Neuropsychological Society</i> , <b>2015</b> , 21, 137-45	3.1	12
222	The role of tau in the pathological process and clinical expression of Huntington's disease. <i>Brain</i> , <b>2015</b> , 138, 1907-18	11.2	80
221	Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. <i>Neurodegenerative Diseases</i> , <b>2015</b> , 15, 331-8	2.3	8
220	Modelling the natural history of Huntington's disease progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2015</b> , 86, 1143-9	5.5	12
219	Rating Apathy in Huntington's Disease: Patients and Companions Agree. <i>Journal of Huntington's Disease</i> , <b>2015</b> , 4, 49-59	1.9	8
218	Quality of life and mild cognitive impairment in early Parkinson's disease: does subtype matter?. <i>Journal of Parkinson's Disease</i> , <b>2014</b> , 4, 331-6	5.3	19
217	Treating Parkinson's disease in the 21st century: can stem cell transplantation compete?. <i>Journal of Comparative Neurology</i> , <b>2014</b> , 522, 2802-16	3.4	40
216	The spectrum of cognitive impairment in Lewy body diseases. <i>Movement Disorders</i> , <b>2014</b> , 29, 608-21	7	89
215	Anti-amyloid compounds inhibit $\beta$ synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 11897-11905	5.4	62
214	Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. <i>Lancet, The</i> , <b>2014</b> , 383, 1138-46	40	313
213	Developing stem cell therapies for Parkinson's disease: waiting until the time is right. <i>Cell Stem Cell</i> , <b>2014</b> , 15, 539-42	18	28
212	Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 1193-201	24.1	159
211	'The clocks that time us'--circadian rhythms in neurodegenerative disorders. <i>Nature Reviews Neurology</i> , <b>2014</b> , 10, 683-93	15	209
210	Molecular and functional definition of the developing human striatum. <i>Nature Neuroscience</i> , <b>2014</b> , 17, 1804-15	25.5	47
209	Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt- $\beta$ catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease. <i>DMM Disease Models and Mechanisms</i> , <b>2014</b> , 7, 1193-203	4.1	13
208	Gold nanoparticles explore cells: cellular uptake and their use as intracellular probes. <i>Methods</i> , <b>2014</b> , 68, 354-63	4.6	53
207	Targeting impulsivity in Parkinson's disease using atomoxetine. <i>Brain</i> , <b>2014</b> , 137, 1986-97	11.2	93

206	Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. <i>Brain</i> , <b>2014</b> , 137, 1145-55	11.2	77
205	Mutant huntingtin is present in neuronal grafts in Huntington disease patients. <i>Annals of Neurology</i> , <b>2014</b> , 76, 31-42	9.4	130
204	Which patients with Parkinson's disease participate in clinical trials? One centre's experiences with a new cell based therapy trial (TRANSEURO). <i>Journal of Parkinson's Disease</i> , <b>2014</b> , 4, 671-6	5.3	29
203	Mild cognitive impairment and Parkinson's disease--something to remember. <i>Journal of Parkinson's Disease</i> , <b>2014</b> , 4, 651-6	5.3	22
202	Sleep and circadian rhythm regulation in early Parkinson disease. <i>JAMA Neurology</i> , <b>2014</b> , 71, 589-595	17.2	237
201	Neurodegenerative disorders: the Glia way forward. <i>Frontiers in Pharmacology</i> , <b>2014</b> , 5, 157	5.6	2
200	The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?. <i>Frontiers in Pharmacology</i> , <b>2014</b> , 5, 139	5.6	27
199	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , <b>2014</b> , 137, 2743-58	11.2	109
198	Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease. <i>European Journal of Neuroscience</i> , <b>2014</b> , 39, 1042-1056	3.5	77
197	Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. <i>Movement Disorders</i> , <b>2014</b> , 29, 195-202	7	224
196	Revisiting the effects of Parkinson's disease and frontal lobe lesions on task switching: the role of rule reconfiguration. <i>Journal of Neuropsychology</i> , <b>2014</b> , 8, 53-74	2.6	8
195	Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 1071-5	3.6	87
194	The incidence of Parkinson's disease in the North-East of England. <i>Age and Ageing</i> , <b>2014</b> , 43, 257-63	3	21
193	The central clock in patients with Parkinson disease--reply. <i>JAMA Neurology</i> , <b>2014</b> , 71, 1456-7	17.2	3
192	Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , <b>2014</b> , 66, 19-27	7.5	12
191	Putative cortical dopamine levels affect cortical recruitment during planning. <i>Neuropsychologia</i> , <b>2013</b> , 51, 2194-201	3.2	6
190	Determinants of delayed diagnosis in Parkinson's disease. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1978-81	5.5	43
189	How often does music and rhythm improve patients' perception of motor symptoms in Parkinson's disease?. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1404-5	5.5	8

188	L-dopa responsive parkinsonism secondary to a subdural haematoma. <i>Journal of Clinical Neuroscience</i> , <b>2013</b> , 20, 1022-4	2.2	2
187	The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2777-85	5.5	24
186	Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. <i>Progress in Neurobiology</i> , <b>2013</b> , 110, 63-73	10.9	38
185	Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. <i>Brain</i> , <b>2013</b> , 136, 392-9	11.2	201
184	The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study. <i>European Journal of Neurology</i> , <b>2013</b> , 20, 1325-9	6	54
183	Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. <i>Lancet Neurology</i> , <b>2013</b> , 12, 84-91	24.1	242
182	The spectrum of nonmotor symptoms in early Parkinson disease. <i>Neurology</i> , <b>2013</b> , 80, 276-81	6.5	281
181	Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. <i>Neurodegenerative Diseases</i> , <b>2013</b> , 11, 79-92	2.3	281
180	Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. <i>Neurobiology of Disease</i> , <b>2013</b> , 49, 118-27	7.5	24
179	Intracellular SERS nanoprobe for distinction of different neuronal cell types. <i>Nano Letters</i> , <b>2013</b> , 13, 2463-70	11.5	124
178	Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. <i>Brain</i> , <b>2013</b> , 136, 433-43	11.2	32
177	The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 1258-64	5.5	416
176	Can patient-specific transdifferentiated neuronal cells help us understand the cellular pathology of Parkinson's disease?. <i>Future Neurology</i> , <b>2013</b> , 8, 605-607	1.5	
175	The challenges of administering cell-based therapies to patients with Parkinson's disease. <i>NeuroReport</i> , <b>2013</b> , 24, 1000-4	1.7	3
174	Personality affects aspects of health-related quality of life in Parkinson's disease via psychological coping strategies. <i>Journal of Parkinson's Disease</i> , <b>2013</b> , 3, 45-53	5.3	28
173	The relationship between abnormalities of saccadic and manual response times in Parkinson's disease. <i>Journal of Parkinson's Disease</i> , <b>2013</b> , 3, 557-63	5.3	6
172	Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. <i>Journal of Parkinson's Disease</i> , <b>2013</b> , 3, 231-9	5.3	32
171	A new approach to disease-modifying drug trials in Parkinson's disease. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 2364-5	15.9	8

170	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. <i>Movement Disorders</i> , <b>2012</b> , 27, 312-5	7	49
169	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , <b>2012</b> , 27, 349-56	7	1373
168	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 643-50	24.1	37
167	Clinical translation of stem cells in neurodegenerative disorders. <i>Cell Stem Cell</i> , <b>2012</b> , 10, 151-5	18	76
166	Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. <i>Movement Disorders</i> , <b>2012</b> , 27, 1522-9	7	109
165	Stem cells and neurodegenerative diseases: where is it all going?. <i>Regenerative Medicine</i> , <b>2012</b> , 7, 26-31	2.5	13
164	White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. <i>NeuroImage</i> , <b>2012</b> , 62, 1675-84	7.9	93
163	Current status of clinical trials of neural transplantation in Parkinson's disease. <i>Progress in Brain Research</i> , <b>2012</b> , 200, 169-98	2.9	24
162	Deep brain stimulation: eye movements reveal anomalous effects of electrode placement and stimulation. <i>PLoS ONE</i> , <b>2012</b> , 7, e32830	3.7	20
161	Current understanding of the glial response to disorders of the aging CNS. <i>Frontiers in Pharmacology</i> , <b>2012</b> , 3, 95	5.6	4
160	Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , <b>2012</b> , 27, 1173-7	7	31
159	The future of stem cells in neurodegenerative disorders of the central nervous system. <i>Cmaj</i> , <b>2012</b> , 184, 631-2	3.5	1
158	The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. <i>Brain</i> , <b>2012</b> , 135, 2449-57	11.2	52
157	A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 1-10	16.6	65
156	Stem cells and regenerative therapies for Parkinson's disease. <i>Degenerative Neurological and Neuromuscular Disease</i> , <b>2012</b> , 2, 79-92	5.4	2
155	The natural history of treated Parkinson's disease in an incident, community based cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2011</b> , 82, 1112-8	5.5	153
154	The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review. <i>Frontiers in Integrative Neuroscience</i> , <b>2011</b> , 5, 78	3.2	18
153	Dopamine stimulates epidermal growth factor release from adult neural precursor cells derived from the subventricular zone by a disintegrin and metalloprotease. <i>NeuroReport</i> , <b>2011</b> , 22, 956-8	1.7	9

152	The factor structure of the UPDRS as an index of disease progression in Parkinson's disease. <i>Journal of Parkinson's Disease</i> , <b>2011</b> , 1, 75-82	5.3	10
151	Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells. <i>Cell Death and Differentiation</i> , <b>2011</b> , 18, 907-13	12.7	34
150	Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation. <i>Neurobiology of Disease</i> , <b>2011</b> , 41, 407-14	7.5	29
149	Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , <b>2011</b> , 10, 1049-57	24.1	134
148	Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity. <i>Neurobiology of Disease</i> , <b>2011</b> , 43, 79-85	7.5	42
147	Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. <i>Current Neurology and Neuroscience Reports</i> , <b>2011</b> , 11, 211-7	6.6	76
146	Coping processes and health-related quality of life in Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , <b>2011</b> , 26, 247-55	3.9	41
145	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. <i>Human Brain Mapping</i> , <b>2011</b> , 32, 258-70	5.9	147
144	Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. <i>Hippocampus</i> , <b>2011</b> , 21, 233-8	3.5	54
143	Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1249-58	4	13
142	Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. <i>Brain</i> , <b>2011</b> , 134, 137-42	11.2	95
141	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 345-53	5.6	178
140	Parkinson's disease--the continuing search for biomarkers. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2011</b> , 49, 393-401	5.9	11
139	Cell-based therapies for Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2011</b> , 11, 831-44	4.3	38
138	Habitual versus goal-directed action control in Parkinson disease. <i>Journal of Cognitive Neuroscience</i> , <b>2011</b> , 23, 1218-29	3.1	88
137	Neural grafting in Parkinson's disease Problems and possibilities. <i>Progress in Brain Research</i> , <b>2010</b> , 184, 265-94	2.9	97
136	Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. <i>American Journal of Neuroradiology</i> , <b>2010</b> , 31, 1036-41	4.4	69
135	Top-down attentional control in Parkinson's disease: salient considerations. <i>Journal of Cognitive Neuroscience</i> , <b>2010</b> , 22, 848-59	3.1	63

134	The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease. <i>Neurobiology of Aging</i> , <b>2010</b> , 31, 1064-8	5.6	33
133	Patients beware: commercialized stem cell treatments on the web. <i>Cell Stem Cell</i> , <b>2010</b> , 7, 43-9	18	46
132	Graft-induced dyskinesias in Parkinson's disease: what is it all about?. <i>Cell Stem Cell</i> , <b>2010</b> , 7, 148-9	18	23
131	Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson's disease and its treatment?. <i>NeuroImage</i> , <b>2010</b> , 52, 1015-26	7.9	104
130	Adult neurogenesis is unaffected by a functional knock-out of MHC class I in mice. <i>NeuroReport</i> , <b>2010</b> , 21, 349-53	1.7	8
129	How vital is sleep in Huntington's disease?. <i>Journal of Neurology</i> , <b>2010</b> , 257, 882-97	5.5	42
128	Parkinson's disease and 2009: recent advances. <i>Journal of Neurology</i> , <b>2010</b> , 257, 1224-8	5.5	3
127	Huntington's disease: changes in saccades and hand-tapping over 3 years. <i>Journal of Neurology</i> , <b>2010</b> , 257, 1890-8	5.5	41
126	Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. <i>Lancet Neurology</i> , <b>2010</b> , 9, 1200-1213	24.1	618
125	Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. <i>Neurobiology of Disease</i> , <b>2010</b> , 37, 356-61	7.5	49
124	The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease. <i>Neuropsychologia</i> , <b>2010</b> , 48, 2719-29	3.2	93
123	Parkinson's disease and healthy aging: independent and interacting effects on action selection. <i>Human Brain Mapping</i> , <b>2010</b> , 31, 1886-99	5.9	24
122	Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 888-95	7	12
121	Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain. <i>Cell Cycle</i> , <b>2009</b> , 8, 2888-94	4.7	80
120	Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease. <i>Neuropsychologia</i> , <b>2009</b> , 47, 1117-27	3.2	49
119	Health-related quality of life in Huntington's disease: Which factors matter most?. <i>Movement Disorders</i> , <b>2009</b> , 24, 574-8	7	94
118	Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. <i>Journal of Neurology</i> , <b>2009</b> , 256, 203-12	5.5	48
117	Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. <i>Journal of Neurology</i> , <b>2009</b> , 256, 493-8	5.5	116



116	No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease. <i>Journal of Neurology</i> , <b>2009</b> , 256, 132-3	5.5	6
115	Biomarkers in Huntington's and Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1180, 97-110	6.5	21
114	Graft outcomes influenced by co-expression of Pax7 in graft and host tissue. <i>Journal of Anatomy</i> , <b>2009</b> , 214, 396-405	2.9	3
113	"The eyes have it". Saccadometry and Parkinson's disease. <i>Experimental Neurology</i> , <b>2009</b> , 219, 382-4	5.7	2
112	A pathophysiological model of freezing of gait in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2009</b> , 15, 333-8	3.6	209
111	Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity. <i>Journal of Clinical Neuroscience</i> , <b>2009</b> , 16, 620-5	2.2	50
110	A functional role for adult hippocampal neurogenesis in spatial pattern separation. <i>Science</i> , <b>2009</b> , 325, 210-3	33.3	1167
109	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 8754-9	11.5	158
108	Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease. <i>NeuroImage</i> , <b>2009</b> , 47, 1659-65	7.9	38
107	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. <i>Brain</i> , <b>2009</b> , 132, 2958-69	11.2	701
106	Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 83, 663-5	6.1	20
105	Defective emotion recognition in early HD is neuropsychologically and anatomically generic. <i>Neuropsychologia</i> , <b>2008</b> , 46, 2152-60	3.2	84
104	The search for a curative cell therapy in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , <b>2008</b> , 265, 32-42	3.2	29
103	Neurotrophic factors as a therapeutic target for Parkinson's disease. <i>Expert Opinion on Therapeutic Targets</i> , <b>2008</b> , 12, 437-47	6.4	60
102	Increased thirst and drinking in Huntington's disease and the R6/2 mouse. <i>Brain Research Bulletin</i> , <b>2008</b> , 76, 70-9	3.9	75
101	The search for biomarkers in Parkinson's disease: a critical review. <i>Expert Review of Neurotherapeutics</i> , <b>2008</b> , 8, 1841-52	4.3	24
100	Hypothalamic involvement in Huntington's disease: an in vivo PET study. <i>Brain</i> , <b>2008</b> , 131, 2860-9	11.2	137
99	Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition. <i>Brain</i> , <b>2008</b> , 131, 2094-105	11.2	153

98	Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. <i>Brain</i> , <b>2008</b> , 131, 397-408	11.2	145
97	The Cambridge Behavioural Inventory revised. <i>Dementia E Neuropsychologia</i> , <b>2008</b> , 2, 102-107	2.1	119
96	The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. <i>Psychopharmacology</i> , <b>2008</b> , 197, 279-93	4.7	38
95	The effects of modafinil on mood and cognition in Huntington's disease. <i>Psychopharmacology</i> , <b>2008</b> , 199, 29-36	4.7	26
94	Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. <i>Journal of Neurology</i> , <b>2008</b> , 255, 1145-52	5.5	28
93	Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. <i>Annals of Neurology</i> , <b>2007</b> , 62, 145-53	9.4	223
92	Predictors of punning in Parkinson's disease: results from a questionnaire survey. <i>Movement Disorders</i> , <b>2007</b> , 22, 2339-45	7	46
91	Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. <i>Brain Research</i> , <b>2007</b> , 1151, 219-26	3.7	53
90	The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. <i>Neurobiology of Disease</i> , <b>2007</b> , 25, 594-608	7.5	28
89	Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson's disease. <i>Journal of Neurology</i> , <b>2007</b> , 254, 846-8	5.5	19
88	Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. <i>Brain</i> , <b>2007</b> , 130, 1787-98	11.2	705
87	Established and emerging therapies for Huntington's disease. <i>Current Molecular Medicine</i> , <b>2007</b> , 7, 579-87.5	12	
86	L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 180-9	8.7	230
85	Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. <i>Nature Clinical Practice Neurology</i> , <b>2007</b> , 3, 250-1		1
84	Microglial activation in presymptomatic Huntington's disease gene carriers. <i>Brain</i> , <b>2007</b> , 130, 1759-66	11.2	324
83	The future of cell therapies in the treatment of Parkinson's disease. <i>Expert Opinion on Biological Therapy</i> , <b>2007</b> , 7, 1487-98	5.4	15
82	Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 4832-8	6.6	159
81	Pax7 expression in the adult rat superior colliculus following optic nerve injury. <i>NeuroReport</i> , <b>2007</b> , 18, 105-9	1.7	10

80	The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. <i>Cell Transplantation</i> , <b>2007</b> , 16, 461-74	4	45
79	Saccadometry: a new tool for evaluating presymptomatic Huntington patients. <i>NeuroReport</i> , <b>2007</b> , 18, 1133-6	1.7	37
78	Imaging microglial activation in Huntington's disease. <i>Brain Research Bulletin</i> , <b>2007</b> , 72, 148-51	3.9	103
77	The use of quantitative oculometry in the assessment of Huntington's disease. <i>Experimental Brain Research</i> , <b>2006</b> , 169, 237-45	2.3	43
76	Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. <i>Experimental Brain Research</i> , <b>2006</b> , 174, 7-18	2.3	78
75	Impaired dimensional selection but intact use of reward feedback during visual discrimination learning in Parkinson's disease. <i>Neuropsychologia</i> , <b>2006</b> , 44, 1290-304	3.2	27
74	Huntington's disease patients have selective problems with insight. <i>Movement Disorders</i> , <b>2006</b> , 21, 385-97		70
73	Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. <i>CNS Drugs</i> , <b>2006</b> , 20, 477-505	6.7	90
72	No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. <i>American Journal of Human Genetics</i> , <b>2006</b> , 78, 1088-90; author reply 1092-4	11	42
71	Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. <i>Brain</i> , <b>2006</b> , 129, 877-86	11.2	155
70	The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease. <i>Neuropsychology</i> , <b>2006</b> , 20, 578-88	3.8	48
69	Transplanted human neural precursor cells migrate widely but show no lesion-specific tropism in the 6-hydroxydopamine rat model of Parkinson's disease. <i>Cell Transplantation</i> , <b>2006</b> , 15, 579-93	4	15
68	Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease. <i>NeuroReport</i> , <b>2006</b> , 17, 1623-7	1.7	16
67	Neural transplantation in Huntington's disease: the NEST-UK donor tissue microbiological screening program and review of the literature. <i>Cell Transplantation</i> , <b>2006</b> , 15, 279-94	4	13
66	Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease. <i>Xenotransplantation</i> , <b>2006</b> , 13, 233-47	2.8	11
65	Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. <i>European Journal of Neuroscience</i> , <b>2006</b> , 23, 1829-38	3.5	141
64	Neural transplants for parkinson's disease: what are the issues?. <i>Poiesis &amp; Praxis</i> , <b>2006</b> , 4, 129-143		
63	Cell-based therapies for disorders of the CNS. <i>Expert Opinion on Therapeutic Patents</i> , <b>2005</b> , 15, 1361-1376.8		3

62	The neurological assessment of patients in vegetative and minimally conscious states. <i>Neuropsychological Rehabilitation</i> , <b>2005</b> , 15, 214-23	3.1	4
61	Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. <i>Neuroscience Letters</i> , <b>2005</b> , 381, 294-8	3.3	91
60	Migration of cells from primary transplants of allo- and xenografted foetal striatal tissue in the adult rat brain. <i>European Journal of Neuroscience</i> , <b>2005</b> , 21, 1503-10	3.5	13
59	Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. <i>Neuropsychologia</i> , <b>2005</b> , 43, 823-32	3.2	226
58	A genome wide linkage disequilibrium screen in Parkinson's disease. <i>Journal of Neurology</i> , <b>2005</b> , 252, 597-602	5.5	7
57	The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease. <i>Journal of Neurology</i> , <b>2005</b> , 252, 642-7	5.5	32
56	The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. <i>Journal of Neurology</i> , <b>2005</b> , 252, 833-8	5.5	90
55	The basal ganglia and rule-governed language use: evidence from vascular and degenerative conditions. <i>Brain</i> , <b>2005</b> , 128, 584-96	11.2	136
54	Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 157-63	6.6	322
53	Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 11564-76	6.6	113
52	New therapeutic approaches to Parkinson's disease including neural transplants. <i>Neurorehabilitation and Neural Repair</i> , <b>2005</b> , 19, 155-81	4.7	16
51	Biomarkers and Parkinson's disease. <i>Brain</i> , <b>2004</b> , 127, 1693-705	11.2	122
50	The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. <i>Brain</i> , <b>2004</b> , 127, 550-60	11.2	523
49	Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue. <i>Xenotransplantation</i> , <b>2004</b> , 11, 60-71	2.8	11
48	Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. <i>European Journal of Neuroscience</i> , <b>2004</b> , 19, 755-60	3.5	213
47	The future challenges in Parkinson's disease. <i>Journal of Neurology</i> , <b>2004</b> , 251, 361-5	5.5	1
46	Immune problems in central nervous system cell therapy. <i>NeuroRx</i> , <b>2004</b> , 1, 472-81		154
45	The cellular repair of the brain in Parkinson's disease--past, present and future. <i>Transplant Immunology</i> , <b>2004</b> , 12, 321-42	1.7	38

44	Pseudo-neglect in Huntington's disease correlates with decreased angular gyrus density. <i>NeuroReport</i> , <b>2004</b> , 15, 1061-4	1.7	11
43	Decreased hippocampal cell proliferation in R6/1 Huntington's mice. <i>NeuroReport</i> , <b>2004</b> , 15, 811-3	1.7	131
42	Random number generation in patients with symptomatic and presymptomatic Huntington's disease. <i>Cognitive and Behavioral Neurology</i> , <b>2004</b> , 17, 208-12	1.6	6
41	Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. <i>Brain</i> , <b>2003</b> , 126, 1127-35	11.2	180
40	Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. <i>Cell Transplantation</i> , <b>2003</b> , 12, 687-95	4	29
39	Staging and preparation of human fetal striatal tissue for neural transplantation in Huntington's disease. <i>Cell Transplantation</i> , <b>2003</b> , 12, 679-86	4	21
38	Migration and differentiation of transplanted human neural precursor cells. <i>NeuroReport</i> , <b>2003</b> , 14, 1257-62	1.6	16
37	Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 6351-6	6.6	419
36	Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease. <i>Experimental Brain Research</i> , <b>2003</b> , 151, 204-17	2.3	34
35	Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. <i>Neuropsychologia</i> , <b>2003</b> , 41, 645-54	3.2	151
34	L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. <i>Neuropsychologia</i> , <b>2003</b> , 41, 1431-41	3.2	403
33	A case of unilateral neglect in Huntington's disease. <i>Neurocase</i> , <b>2003</b> , 9, 261-73	0.8	13
32	The future of cell-based transplantation therapies for neurodegenerative disorders. <i>Journal of Hematotherapy and Stem Cell Research</i> , <b>2003</b> , 12, 635-42		21
31	Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. <i>Journal of Cognitive Neuroscience</i> , <b>2003</b> , 15, 629-42	3.1	32
30	Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. <i>Neuropsychologia</i> , <b>2002</b> , 40, 1277-84	3.2	81
29	Repairing the brain in Parkinson's disease: where next?. <i>Movement Disorders</i> , <b>2002</b> , 17, 233-41	7	27
28	Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. <i>European Journal of Neuroscience</i> , <b>2002</b> , 15, 1255-66	3.5	62
27	The heterogeneity of idiopathic Parkinson's disease. <i>Journal of Neurology</i> , <b>2002</b> , 249, 138-45	5.5	149

26	Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2002</b> , 73, 678-85	5.5	144
25	Alpha Gal is widely expressed in embryonic porcine stem cells and neural tissue. <i>NeuroReport</i> , <b>2002</b> , 13, 481-5	1.7	9
24	Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. <i>Brain</i> , <b>2002</b> , 125, 584-94	11.2	341
23	Neural transplantation therapies for Parkinson's and Huntington's diseases. <i>Drug Discovery Today</i> , <b>2001</b> , 6, 575-582	8.8	4
22	Prospects for the treatment of Parkinson's disease using neurotrophic factors. <i>Expert Opinion on Pharmacotherapy</i> , <b>2001</b> , 2, 1531-43	4	13
21	Porcine neural xenografts in the immunocompetent rat: immune response following grafting of expanded neural precursor cells. <i>Neuroscience</i> , <b>2001</b> , 106, 201-16	3.9	59
20	Cellular and molecular aspects of striatal development. <i>Brain Research Bulletin</i> , <b>2001</b> , 55, 533-40	3.9	40
19	Neurodegeneration: a failure of neuroregeneration?. <i>Lancet, The</i> , <b>2001</b> , 358, 1174-6	40	95
18	Stem cell transplantation as an approach to brain repair. <i>Expert Opinion on Therapeutic Patents</i> , <b>2001</b> , 11, 1563-1582	6.8	5
17	Mechanisms of cognitive set flexibility in Parkinson's disease. <i>Brain</i> , <b>2001</b> , 124, 2503-12	11.2	283
16	Neural tissue xenotransplantation: what is needed prior to clinical trials in Parkinson's disease? Neural Tissue Xenografting Project. <i>Cell Transplantation</i> , <b>2000</b> , 9, 235-46	4	31
15	Hibernated human fetal striatal tissue: successful transplantation in a rat model of Huntington's disease. <i>Cell Transplantation</i> , <b>2000</b> , 9, 743-9	4	27
14	A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease. <i>Journal of Neuroscience</i> , <b>2000</b> , 20, 3415-24	6.6	64
13	Prospects for the treatment of Parkinson's disease using neural grafts. <i>Expert Opinion on Pharmacotherapy</i> , <b>2000</b> , 1, 889-902	4	10
12	Fetal porcine dopaminergic cell survival in vitro and its relationship to embryonic age. <i>Cell Transplantation</i> , <b>1999</b> , 8, 593-9	4	14
11	The rejection of neural xenotransplants: a role for antibodies. <i>Transplantation</i> , <b>1999</b> , 68, 1091-2	1.8	5
10	An unusual cause for a painful diplopia. <i>Postgraduate Medical Journal</i> , <b>1998</b> , 74, 177-8	2	
9	Successful treatment of intractable epilepsy partialis continua with multiple subpial transections. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>1998</b> , 65, 137-8	5.5	25

8	Successful treatment of stiff man syndrome with intravenous immunoglobulin. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>1997</b> , 62, 426-7	5.5	29
7	Survival of Nigral Grafts within the Striatum of Marmosets with 6-OHda Lesions Depends Critically on Donor Embryo Age. <i>Cell Transplantation</i> , <b>1997</b> , 6, 557-569	4	38
6	Proton magnetic resonance spectroscopy in a pathologically confirmed acute demyelinating lesion. <i>Journal of Neurology</i> , <b>1997</b> , 244, 204-7	5.5	22
5	Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon. <i>Experimental Brain Research</i> , <b>1995</b> , 106, 275-82	2.3	91
4	A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures, and in vivo grafts. <i>Cell Transplantation</i> , <b>1995</b> , 4, 173-200	4	25
3	Neurotrophic factors and neural grafts: a growing field. <i>Seminars in Neuroscience</i> , <b>1993</b> , 5, 431-441		8
2	Metastatic non-seminomatous germ cell tumour and dermatomyositis. <i>Postgraduate Medical Journal</i> , <b>1990</b> , 66, 59-60	2	4
1	MEIS-WNT5A axis regulates development of 4th ventricle choroid plexus		3